MAPT and dementia: However, the use of varied biomarker panels comprised of NF-L, total and phosphorylated tau, and Aβ1-42 improved discrimination between AD dementia, FTD, and some other types of dementia [118,127,128] and increased sensitivity in AD stage differentiation using NF-L and fatty acid binding protein 3 [129].